Breakthrough in the discovery of Nav1.8 non-opioid chronic pain drugs

The development of non-opioid chronic pain drugs is undergoing amazing advancements at the moment. Chronic pain can now be effectively treated without the use of opioids, which is truly groundbreaking for future pain therapeutics.

Two weeks ago, Vertex Pharmaceuticals announced promising clinical phase III results for VX-548, a Nav1.8 inhibitor for acute and chronic pain. Moreover, last week, Latigo Biotherapeutics announced it secured $135 million Series A financing to develop non-opioid novel pain therapeutics, spear-headed by LTG-001, a Nav1.8 selective inhibitor.

Research on ion channels and pain drug discovery can be conducted using Sophion Bioscience automated patch clamp instrumentation.

Are you interested in learning more about Nav1.8 and other Nav channel recordings?

Read a recent paper from Latigo Biotherapeutics here
See ourr QPatch comparison poster for Nav1.1 and Nav1.8 here